Fact check
“The final rule distinguished between marijuana products based on intended use, despite the products being pharmacologically identical.”
Reasoning
The provided evidence quotes the final rule's distinction based on intended use and notes that the products are pharmacologically identical, directly confirming the claim.
On confidence: The claim is directly corroborated by the excerpts, giving high confidence.
Important context
The final rule limited Schedule III eligibility to marijuana products sold by state-licensed dispensaries or FDA-approved, despite identical pharmacology, highlighting a use‑based classification.
Evidence
Supporting (2)
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
"potential for abuse," recommended placing it in Schedule III, which includes prescription drugs such as ketamine, anabolic steroids, and Tylenol with codeine. Last April, Acting Attorney General Todd Blanche issued a final rule that…
- Tier 1 — Primary sourceFederal drug scheduling relies on vague criteria, GAO report finds
identical, distinguished only by their intended use. By contrast, cocaine, fentanyl, and methamphetamine are all Schedule II drugs, regardless of whether they are dispensed by pharmacies based on medical prescriptions or purchased on the…
Limitations
Both excerpts come from a single source; no additional independent verification is available within the supplied evidence. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.
- Last verified:
- Oct 1, 2026, 4:49 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Hazy Drug Classification Criteria Invite Dubious Bureaucratic JudgmentsReason · Jacob Sullum